PSP Research LLC Acquires Shares of 20,368 Celldex Therapeutics, Inc. $CLDX

PSP Research LLC acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the fourth quarter, Holdings Channel reports. The fund acquired 20,368 shares of the biopharmaceutical company’s stock, valued at approximately $553,000. Celldex Therapeutics makes up approximately 0.5% of PSP Research LLC’s holdings, making the stock its 7th largest position.

Other hedge funds also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd purchased a new stake in Celldex Therapeutics during the third quarter valued at about $26,000. Wilmington Savings Fund Society FSB purchased a new stake in Celldex Therapeutics during the third quarter valued at about $42,000. Russell Investments Group Ltd. lifted its position in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Celldex Therapeutics in the third quarter worth approximately $63,000. Finally, Strs Ohio purchased a new stake in shares of Celldex Therapeutics in the third quarter worth approximately $75,000.

Wall Street Analyst Weigh In

CLDX has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Stifel Nicolaus reissued a “buy” rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Wolfe Research raised shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target for the company in a research report on Monday, March 23rd. Finally, Wells Fargo & Company increased their price target on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.78.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $30.15 on Wednesday. The stock’s 50 day moving average price is $32.01 and its 200 day moving average price is $28.15. Celldex Therapeutics, Inc. has a 52 week low of $18.55 and a 52 week high of $35.79. The company has a market capitalization of $2.37 billion, a P/E ratio of -7.08 and a beta of 0.98.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.